SolventumSOLV

Key highlights

• Profit outlook raised: Management raised its full year profit forecast to a range between $7.10 and $7.20 per share, up from the previous top end of $6.60. This increase reflects better performance in the core business and higher expected cash flow, which is now predicted to be between $200 million and $300 million.
• Dental segment surge: The dental solutions business grew organic sales, which excludes the impact of currency and big business deals, by 15.2% this quarter. This was a major jump from the 9.4% growth seen in the first half of the year, driven by higher demand and volume for dental and orthodontic products.
• Operating margins expanding: Adjusted operating margins, a measure of how much profit is left after paying for business operations, reached 28.4% compared to 21.9% a year ago. A one time refund on import taxes and better efficiency helped drive this 650 basis point improvement.
• Major division separation: The company announced it will separate its Health Information Systems business, which grew organic sales by 5.4% this quarter to reach $354 million. This move is designed to make the company a more focused medical technology business by shedding the software and data visualization arm.
• Broad organic growth: Total organic sales grew 9.5% in the quarter, though some of this was due to customers placing early orders for $2.21 billion in products ahead of a technology system update. Even without these early orders, every main business segment reported growth for the period.

Our take: A very strong quarter that shows the business is running much more efficiently as an independent company. The massive jump in profit guidance and the plan to spin off the software division signal that management is moving quickly to unlock value. This performance reinforces the case for owning the stock long term.